URINASTATIN
Urinastatin (ulinastatin) is a protease inhibitor reducing inflammation and oxidative stress, used in pancreatitis and sepsis. Side effects include rash, fever, hypotension, and rare anaphylaxis. Only GMP materials will be supplied, logistics all according to GDP.
About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of Action
URINASTATIN demonstrates multilayer biochemical influence across signalling hierarchies, catalyticdomain regulation, mitochondrialnetwork energetics, iongradient stability, membrane electrochemistry, redox equilibrium and transcriptionfactor axis alignment. Its molecular topology enables interaction with catalytic residues, allosteric nodes, hydrophobic receptor microdomains, transmembrane helices, redoxbuffer matrices and cytoskeletal scaffolds, resulting in widespectrum modulation across metabolic, structural, electrophysiological and genomic systems.
Mechanistically, URINASTATIN may remodel phosphorylation flux across MAPK/ERK/JNK/p38 pathways, reshape PI3KAKT survival topology, modify Gprotein coupling dynamics, reorganise Ca²⁺ signalling microdomains, influence IP/DAG cascade geometry and adjust cAMPPKA amplitude distributions. Mitochondrial impacts include ETCcomplex rebalancing, ATP/ADP turnover pattern shifts, ROSthreshold displacement, membranepotential polarity modulation and ERmitochondrial stresscrosstalk regulation.
Advanced
- Kinomescale interference mapping and catalyticcascade simulation
- Highresolution docking and conformationaltransition modelling
- UPR/ERstress, autophagymitophagy and organellenetwork integration research
- Multiomics regulatory reconstruction (RNAseq, phosphoproteomics, metabolomics, proteomics)
- Cytoskeletal tensionmapping and polymerturnover analysis
- Cellfate simulations (apoptosis, necroptosis, ferroptosis, parthanatos)
- Machinelearning SAR/QSAR predictive optimisation
Toxicodynamics & Hazard Profile
- Accelerated ROS accumulation & antioxidantbuffer saturation
- Mitochondrial fragmentation or ETCaxis destabilisation
- Severe Na⁺/K⁺/Ca²⁺ ionic-flux dysregulation
- Cytoskeletal collapse & membrane-integrity failure
- Inflammatoryaxis hyperactivation (NF-κB, STAT, IRF pathways)
- Activation of multiaxis programmed-cell-death pathways
- Epigenetic methylation/acetylation drift
For expert laboratory research only not intended for biological or therapeutic exposure.
Only GMP materials will be supplied, logistics all according to GDP.
Datasheet
| Molecular Formula | Protein |
|---|---|
| Molecular Weight | 220.26 g/mol |
| CAS Number | 80449-07-0 |
| Storage Condition | Store at 28°C |
| Solubility | Soluble in water |
| Purity | Purity information is available upon request (COA). |
| Synonym | Uti(68); Acid-stable protease inhibitor; Uristatin; Mingin; Urinary trypsin inhibitor (68) |
| IUPAC/Chemical Name | Kunitztype protease inhibitor |
| InChl Key | Unavailable |
| InChl Code | Unavailable |
| References | PubChem; ChemBL; FDA; |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.


